Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]. Blood. 2023;142(suppl 1):7414.

doi:10.1182/blood.2024025087

Skip Nav Destination

ERRATUM| June 20, 2024

Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]. Blood. 2023;142(suppl 1):7414.

Blood (2024) 143 (25): 2676.

https://doi.org/10.1182/blood.2024025087

The last author of this American Society of Hematology Annual Meeting abstract, Supreet Kaur, should not be listed as an author. The last author should be Zohra Nooruddin, MD, with University of Texas Health-San Antonio, San Antonio, TX, as the affiliation and no conflicts of interest to disclose.

2024